Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Leif Bjermer, Isabelle H Boucot, François Maltais, Edward M Kerwin, Ian P Naya, Lee Tombs, Paul W Jones, Chris Compton, David A Lipson & Claus F Vogelmeier. (2021) Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 1939-1956.
Read now
Read now
Anthony D. D’Urzo, Dave Singh, James F. Donohue, Kenneth R. Chapman & Robert A. Wise. (2021) Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update. Expert Review of Respiratory Medicine 15:9, pages 1093-1106.
Read now
Read now
Wen-Chien Cheng, Biing-Ru Wu, Wei-Chih Liao, Chih-Yu Chen, Wei-Chun Chen, Te-Chun Hsia, Chih-Yen Tu, Chia-Hung Chen & Wu-Huei Hsu. (2020) When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 3375-3384.
Read now
Read now
Edward M Kerwin, Lindsey Murray, Xiaoli Niu & Carole Dembek. (2020) Clinically Important Deterioration Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Nebulized Glycopyrrolate: A Post Hoc Analysis of Pooled Data from Two Randomized, Double-Blind, Placebo-Controlled Studies. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 2309-2318.
Read now
Read now
Konstantinos Kostikas, Alexander J Mackay, Claus F Vogelmeier, Stefan-Marian Frent, Pritam Gupta, Donald Banerji, Francesco Patalano, Pascal J Pfister & Jadwiga A Wedzicha. (2020) Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 1831-1838.
Read now
Read now
Rongchang Chen, Nanshan Zhong, Hao-Yan Wang, Li Zhao, Xiaodong Mei, Zhiqiang Qin, Juan Huang, Pryseley N Assam, Andrea Maes, Shahid Siddiqui, Ubaldo J Martin & Colin Reisner. (2020) Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 43-56.
Read now
Read now
Neil S. Skolnik, Trang Susan Nguyen, Aarisha Shrestha, Riju Ray, Thomas C. Corbridge & Stephen A. Brunton. (2020) Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β2-agonist bronchodilators. Postgraduate Medicine 132:2, pages 198-205.
Read now
Read now
Dave Singh, Leonardo M Fabbri, Stefano Vezzoli, Stefano Petruzzelli & Alberto Papi. (2019) Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 531-546.
Read now
Read now
Victoria Federico Paly, Ian Naya, Necdet B Gunsoy, Maurice T Driessen, Nancy Risebrough, Andrew Briggs & Afisi S Ismaila. (2019) Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 939-951.
Read now
Read now
Timm Greulich, Konstantinos Kostikas, Mina Gaga, Maryam Aalamian-Mattheis, Nadine S Lossi, Francesco Patalano, Xavier Nunez, Veronica A Pagano, Robert Fogel, Claus F Vogelmeier & Andreas Clemens. (2018) Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 1229-1237.
Read now
Read now
Anthony D D’Urzo, Mario Cazzola, Nicola A Hanania, Roland Buhl & M Reza Maleki-Yazdi. (2018) New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 2805-2819.
Read now
Read now
A Papi, D Dokic, W Tzimas, I Mészáros, A Olech-Cudzik, Z Koroknai, K McAulay, S Mersmann, PS Dalvi & T Overend. (2017) Fluticasone propionate/formoterol for COPD management: a randomized controlled trial. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 1961-1971.
Read now
Read now
Antonio R Anzueto, Claus F Vogelmeier, Konstantinos Kostikas, Karen Mezzi, Sebastian Fucile, Giovanni Bader, Steven Shen, Donald Banerji & Robert Fogel. (2017) The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 1325-1337.
Read now
Read now
Klaus F. Rabe. (2017) GFF MDI for the improvement of lung function in COPD – A look at the PINNACLE-1 and PINNACLE-2 data and beyond. Expert Review of Clinical Pharmacology 10:7, pages 685-698.
Read now
Read now
Articles from other publishers (37)
Dermot A. Linden, Hong Guo-Parke, Michael C. McKelvey, Gisli G. Einarsson, Andrew J. Lee, Derek J. Fairley, Vanessa Brown, Gavin Lundy, Christina Campbell, Danielle Logan, Margaret McFarland, Dave Singh, Daniel F. McAuley, Clifford C. Taggart & Joseph C. Kidney. (2023) Valaciclovir for Epstein-Barr Virus Suppression in Moderate-to-Severe COPD. Chest.
Crossref
Crossref
Wei-Chun Huang, Chih-Yu Chen, Wei-Chih Liao, Biing-Ru Wu, Wei-Chun Chen, Chih-Yen Tu, Chia-Hung Chen & Wen-Chien Cheng. (2022) Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD. Journal of Clinical Medicine 11:23, pages 7165.
Crossref
Crossref
Mario Cazzola & Maria Gabriella Matera. (2022) Clinically important deterioration: a composite tool for managing patients with COPD. Respiratory Medicine 205, pages 107054.
Crossref
Crossref
Marc Miravitlles, Tomotaka Kawayama & Michael Dreher. (2022) LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations. Journal of Clinical Medicine 11:22, pages 6623.
Crossref
Crossref
N. P. Knyazheskaya, E. Кh. Anaev, A. S. Belevskiy & M. A. Makarova. (2022) Double broncholytic combination of umeclidnium/ vilanterol in COPD therapy: issues of efficacy and safety. Meditsinskiy sovet = Medical Council 16:18, pages 49-54.
Crossref
Crossref
Mario Cazzola, Clive Page, Paola Rogliani, Luigino Calzetta & Maria Gabriella Matera. (2022) Dual bronchodilation for the treatment of COPD: From bench to bedside. British Journal of Clinical Pharmacology 88:8, pages 3657-3673.
Crossref
Crossref
François Maltais, Claus F. Vogelmeier, Edward M. Kerwin, Leif H. Bjermer, Paul W. Jones, Isabelle H. Boucot, David A. Lipson, Lee Tombs, Chris Compton & Ian P. Naya. (2022) Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD. Respiratory Medicine 200, pages 106918.
Crossref
Crossref
Fernando J. Martinez, Alvar AgustiBartolome R. CelliMeiLan K. HanJames P. AllinsonSurya P. BhattPeter CalverleySanjay H. Chotirmall, Badrul ChowdhuryPatrick DarkenCarla A. Da SilvaGavin DonaldsonPaul DorinskyMark DransfieldRosa FanerDavid M. HalpinPaul JonesJerry A. Krishnan, Nicholas LocantoreFernando D. MartinezHana MullerovaDavid Price, Klaus F. RabeColin ReisnerDave Singh, Jørgen Vestbo, Claus F. VogelmeierRobert A. Wise, Ruth Tal-Singer & Jadwiga A. Wedzicha. (2022) Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre–Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. American Journal of Respiratory and Critical Care Medicine 205:3, pages 275-287.
Crossref
Crossref
Yuki Abe, Masaru Suzuki, Hironi Makita, Hirokazu Kimura, Kaoruko Shimizu, Satoshi Konno & Masaharu Nishimura. (2021) One‐year clinically important deterioration and long‐term clinical course in Japanese patients with COPD: a multicenter observational cohort study. BMC Pulmonary Medicine 21:1.
Crossref
Crossref
Donald P. Tashkin, Xiaoli Niu, Sanjay Sharma & Shahin Sanjar. (2021) Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD. npj Primary Care Respiratory Medicine 31:1.
Crossref
Crossref
Dave Singh, James F. Donohue, Isabelle H. Boucot, Neil C. Barnes, Chris Compton & Fernando J. Martinez. (2021)
Future concepts in bronchodilation for COPD: dual-
versus
monotherapy
. European Respiratory Review 30:160, pages 210023.
Crossref
Crossref
Courtney Crim, Lucy J. Frith, Dawn Midwinter & James F. Donohue. (2021)
FEV
1
Minimum Important Difference versus Minimal Detectable Difference? In Search of the Unicorn
. American Journal of Respiratory and Critical Care Medicine 203:12, pages 1573-1576.
Crossref
Crossref
MeiLan K. Han, Gerard J. Criner, Mark T. Dransfield, David M.G. Halpin, Christine E. Jones, Sally Kilbride, Peter Lange, Sally Lettis, David A. Lipson, David A. Lomas, Neil Martin, Fernando J. Martinez, Robert A. Wise, Ian P. Naya & Dave Singh. (2021) Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis. ERJ Open Research 7:1, pages 00663-2020.
Crossref
Crossref
Klaus F. Rabe, James D. Chalmers, Marc Miravitlles, Janwillem W. H. Kocks, Ioanna Tsiligianni, Alberto de la Hoz, Wenqiong Xue, Dave Singh, Gary T. Ferguson & Jadwiga Wedzicha. (2020) Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO® Trials. Advances in Therapy 38:1, pages 579-593.
Crossref
Crossref
Mona Bafadhel, Dave Singh, Christine Jenkins, Stefan Peterson, Thomas Bengtsson, Peter Wessman & Malin Fagerås. (2020) Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis. Respiratory Research 21:1.
Crossref
Crossref
Klaus F. Rabe, David M. G. Halpin, MeiLan K. Han, Marc Miravitlles, Dave Singh, Lars Grönke, Florian Voß & Fernando J. Martinez. (2020) Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. Respiratory Research 21:1.
Crossref
Crossref
Dave Singh, Gerard J. Criner, Ian Naya, Paul W. Jones, Lee Tombs, David A. Lipson & MeiLan K. Han. (2020) Measuring disease activity in COPD: is clinically important deterioration the answer?. Respiratory Research 21:1.
Crossref
Crossref
Lisa Joy Juergens, Heinrich Worth & Uwe R. Juergens. (2020) New Perspectives for Mucolytic, Anti-inflammatory and Adjunctive Therapy with 1,8-Cineole in COPD and Asthma: Review on the New Therapeutic Approach. Advances in Therapy 37:5, pages 1737-1753.
Crossref
Crossref
Yi-yang Zhao, Cong Liu, Yu-qin Zeng, Ai-yuan Zhou, Jia-xi Duan, Wei Cheng, Tian Sun, Xin Li, Li-bing Ma, Qi-mi Liu, Ying-qun Zhu, Ming Chen, Mei-ling Zhou & Ping Chen. (2020) Modified and simplified clinically important deterioration: multidimensional indices of short-term disease trajectory to predict future exacerbations in patients with chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease 14, pages 175346662097737.
Crossref
Crossref
Claus F. Vogelmeier, Edward M. Kerwin, Leif H. Bjermer, Lee Tombs, Paul W. Jones, Isabelle H. Boucot, Ian P. Naya, David A. Lipson, Chris Compton, Neil Barnes & François Maltais. (2020)
Impact of baseline COPD symptom severity on the benefit from dual
versus
mono-bronchodilators: an analysis of the EMAX randomised controlled trial
. Therapeutic Advances in Respiratory Disease 14, pages 175346662096850.
Crossref
Crossref
François Maltais, Leif Bjermer, Edward M. Kerwin, Paul W. Jones, Michael L. Watkins, Lee Tombs, Ian P. Naya, Isabelle H. Boucot, David A. Lipson, Chris Compton, Mitra Vahdati-Bolouri & Claus F. Vogelmeier. (2019) Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respiratory Research 20:1.
Crossref
Crossref
Xiaoyao Ma, Aina Liu, Wenjuan Liu, Zhihua Wang, Nianwei Chang, Suyun Li, Jiansheng Li, Yuanyuan Hou & Gang Bai. (2019) Analyze and Identify Peiminine Target EGFR Improve Lung Function and Alleviate Pulmonary Fibrosis to Prevent Exacerbation of Chronic Obstructive Pulmonary Disease by Phosphoproteomics Analysis. Frontiers in Pharmacology 10.
Crossref
Crossref
Usman Maqsood, Terence N Ho, Karen Palmer, Fiona JR Eccles, Mohammed Munavvar, Ran Wang, Iain Crossingham & David JW Evans. (2019) Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2019:3.
Crossref
Crossref
Ian P. Naya, Lee Tombs, Hana Muellerova, Christopher Compton & Paul W. Jones. (2018) Long-term outcomes following first short-term clinically important deterioration in COPD. Respiratory Research 19:1.
Crossref
Crossref
Antonio R. Anzueto, Konstantinos Kostikas, Karen Mezzi, Steven Shen, Michael Larbig, Francesco Patalano, Robert Fogel, Donald Banerji & Jadwiga A. Wedzicha. (2018) Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study. Respiratory Research 19:1.
Crossref
Crossref
Bernardino Alcázar Navarrete, Isabelle Boucot, Ian Naya, Lee Tombs, David A. Lipson, Chris Compton, Ana R. Sousa & Gregory Feldman. (2018) Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis. Pulmonary Therapy 4:2, pages 171-183.
Crossref
Crossref
Ian Naya, Chris Compton, Afisi S. Ismaila, Ruby Birk, Noushin Brealey, Maggie Tabberer, Chang-Qing Zhu, David A. Lipson & Gerard Criner. (2018) Preventing clinically important deterioration with single-inhaler triple therapy in COPD. ERJ Open Research 4:4, pages 00047-2018.
Crossref
Crossref
Ian P. Naya, Lee Tombs, David A. Lipson & Chris Compton. (2018) Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis. Advances in Therapy 35:10, pages 1626-1638.
Crossref
Crossref
I. Gonçalves, M.J. Guimarães, M. van Zeller, F. Menezes, J. Moita & P. Simão. (2018) Clinical and molecular markers in COPD. Pulmonology 24:4, pages 250-259.
Crossref
Crossref
Fernando J. Martinez, MeiLan K. Han, James P. Allinson, R. Graham Barr, Richard C. Boucher, Peter M. A. Calverley, Bartolome R. Celli, Stephanie A. Christenson, Ronald G. Crystal, Malin Fagerås, Christine M. Freeman, Lars Groenke, Eric A. Hoffman, Mehmet Kesimer, Kostantinos Kostikas, Robert PaineIIIIII, Shahin Rafii, Stephen I. Rennard, Leopoldo N. Segal, Renat Shaykhiev, Christopher Stevenson, Ruth Tal-Singer, Jørgen Vestbo, Prescott G. Woodruff, Jeffrey L. Curtis & Jadwiga A. Wedzicha. (2018) At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine 197:12, pages 1540-1551.
Crossref
Crossref
Anthony D’Urzo, Giovanni Bader, Steven Shen, Pankaj Goyal & Pablo Altman. (2018) Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials. npj Primary Care Respiratory Medicine 28:1.
Crossref
Crossref
Steven D. Deas & Nikhil Huprikar. (2018) Dual bronchodilator therapy for chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine 24:2, pages 130-137.
Crossref
Crossref
Sara Roversi, Lorenzo Corbetta & Enrico Clini. (2017) GOLD 2017 recommendations for COPD patients: toward a more personalized approach. COPD Research and Practice 3:1.
Crossref
Crossref
Dave Singh, Anthony D. D’Urzo, Ferran Chuecos, Anna Muñoz & Esther Garcia Gil. (2017) Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. Respiratory Research 18:1.
Crossref
Crossref
Gregory J. Feldman, Ana R. Sousa, David A. Lipson, Lee Tombs, Neil Barnes, John H. Riley, Sadhana Patel, Ian Naya, Chris Compton & Bernardino Alcázar Navarrete. (2017) Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study. Advances in Therapy 34:11, pages 2518-2533.
Crossref
Crossref
Han Ni, Aung Htet & Soe Moe. (2017) Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews 2017:6.
Crossref
Crossref
M. Reza Maleki-Yazdi, Dave Singh, Antonio Anzueto, Lee Tombs, William A. Fahy & Ian Naya. (2016) Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials. Advances in Therapy 33:12, pages 2188-2199.
Crossref
Crossref